查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1423777

带状疱疹后神经痛治疗的全球市场 - 全球产业分析、规模、份额、成长、趋势、预测 (2031) - 按治疗类型、按分销管道、按地区

Post Herpetic Neuralgia Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 214 Pages | 商品交期: 2-5个工作天内

价格
简介目录

带状疱疹后神经痛 (PHN) 的特征是由于水痘带状疱疹病毒（带状疱疹）重新激活导致周围神经损伤而引起的中度至重度神经痛。 PHN 是带状疱疹重新活化后持续超过 30 天的神经痛。 全球带状疱疹后神经痛治疗市场主要由辉瑞公司、梯瓦製药工业有限公司、Mylan N.V.和Endo Pharmaceuticals Inc.等主要製造商推动，这些製造商合计占市场收入的50%。 这些领先的製造商正在利用人们对带状疱疹后神经痛治疗的认识不断增强以及老年人口不断增长的趋势。

虽然带状疱疹后神经痛治疗市场由大型供应商主导，但由于专利到期以及与治疗方案相关的功效和效率挑战，整合并不一定会转化为盈利能力的增加。 然而，随着带状疱疹后神经痛治疗意识的增强，市场动态正在发生变化，尤其是在老年人中。

由于带状疱疹后神经痛盛行率上升和老年人口不断扩大，全球带状疱疹后神经痛治疗市场正在成长。 此外，全球医疗保健基础设施的改善和政府对带状疱疹后神经痛治疗产品的支持预计将推动市场成长。

带状疱疹后神经痛治疗市场的关键驱动因素是筛检率的提高和老年人口的增加。 根据疾病管制与预防中心的数据，美国成年人的带状疱疹发病率呈上升趋势，大约三分之一的人在一生中患有带状疱疹。 大部分带状疱疹病例会导致带状疱疹后神经痛，尤其是 50 岁以上的人。

儘管市场潜力巨大，但对阿片类药物使用和用药过量死亡率上升的担忧是带状疱疹后神经痛治疗市场的主要限制因素。 阿片类药物过量死亡占药物过量死亡的很大一部分，引起了人们对治疗选择的担忧。

本报告考察了全球带状疱疹后神经痛治疗市场，并提供了市场概况，包括按治疗类型、分销渠道、地区划分的趋势以及进入市场的公司的竞争趋势。Masu。

目录

第 1 章执行摘要

第2章市场概述

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • 新冠肺炎 (COVID-19) 影响分析
  • 乌克兰和俄罗斯之间衝突的影响
  • 经济概况
  • 杵分析

第3章2018-2031年全球带状疱疹后神经痛治疗市场展望

  • 2018-2031 年全球带状疱疹后神经痛治疗市场展望（按治疗类型、价值（十亿美元））
  • 2018-2031 年全球带状疱疹后神经痛治疗市场展望，按分销管道划分，价值（十亿美元）
  • 2018-2031 年全球带状疱疹后神经痛治疗市场展望（按地区、价值（十亿美元））

第4章2018-2031年北美带状疱疹后神经痛治疗市场前景

第5章欧洲带状疱疹后神经痛治疗市场前景，2018-2031

第6章亚太地区带状疱疹后神经痛治疗市场展望，2018-2031

第 7 章拉丁美洲带状疱疹后神经痛治疗市场展望，2018-2031

第8章中东与非洲带状疱疹后神经痛治疗市场前景，2018-2031

第9章竞争态势

  • 治疗类型和分销管道的热图
  • 製造商和分销通路热图
  • 2023 年公司市占率分析
  • 竞争对手仪表板
  • 公司简介
    • Pfizer Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Mylan N.V.
    • Endo Pharmaceuticals Inc.
    • Daiichi Sankyo
    • Acorda Therapeutics
    • Purdue Pharma L.P
    • Teikoku Pharma USA, Inc.
    • Janssen Pharmaceuticals, Inc.

第10章 附录

简介目录

Post herpetic neuralgia (PHN) is characterized by moderate to severe nerve pain resulting from damage to a peripheral nerve due to the reactivation of the varicella zoster virus (shingles). PHN is nerve pain that persists for more than 30 days after the reactivation of herpes zoster.The global post herpetic neuralgia treatment market is predominantly driven by key players, including Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., and Endo Pharmaceuticals Inc., who collectively account for more than 50% of the market's revenue. These leading manufacturers are capitalizing on growing awareness about post herpetic neuralgia treatment and the increasing geriatric population.

Market Consolidation and Challenges

While large vendors dominate the post herpetic neuralgia treatment market, consolidation hasn't necessarily translated into increased profitability due to patent expirations and the effectiveness and efficiency challenges associated with treatment options. However, the market's dynamics are evolving as awareness about post herpetic neuralgia treatment grows, especially among the elderly.

Drivers of Market Growth

The global post herpetic neuralgia treatment market is experiencing growth due to the rising prevalence of post herpetic neuralgia and the expanding geriatric population. Furthermore, the development of healthcare infrastructure globally, coupled with government support for post herpetic neuralgia treatment products, is expected to drive market growth.

Growing Geriatric Population and Screening Rates

The increasing rates of screening and the growth in the geriatric population are critical drivers of the post herpetic neuralgia treatment market. According to the Center for Disease Control and Prevention, shingles is on the rise among adults in the United States, with approximately 1 in 3 people developing shingles in their lifetime. A significant percentage of shingles cases result in post herpetic neuralgia, particularly in individuals aged 50 and older.

Concerns Over Opioid Use

Despite the market's potential, concerns over opioid use and the rising mortality rates due to overdoses pose significant constraints on the post herpetic neuralgia treatment market. Opioid overdose deaths, accounting for a substantial portion of drug overdose fatalities, have raised concerns over treatment options.

Opportunities in New Drug Development

The development of new drugs presents a significant opportunity in the post herpetic neuralgia treatment market, as a definitive curative treatment is yet to be discovered. Government support for post herpetic neuralgia treatment products, particularly through initiatives and investments in research and development, is expected to foster market growth.

Regional Variations in Market Growth

In developed regions like North America and Europe, the presence of a larger economy, higher purchasing power, and extensive healthcare infrastructure support the growth of the post herpetic neuralgia treatment market. The U.S., in particular, stands out due to excellent reimbursement policies and increasing incidence rates of post herpetic neuralgia. In Asia Pacific, Japan, India, Australia, and New Zealand are key players in the market.

Challenges to Market Realization

Despite the market's potential, challenges remain, particularly related to the efficacy and efficiency of treatment options. While calcium-channel blockers, tricyclic antidepressants, steroids, and opioids are used in post herpetic neuralgia treatment, they have limitations and side effects that restrict their widespread use.

Competitive Analysis

The post herpetic neuralgia treatment market features key players such as Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Endo Pharmaceuticals Inc., and others. These players are profiled in the competition section of the report, outlining their market shares, strategies, product offerings, marketing approaches, and company dashboards.

Post Herpetic Neuralgia Treatment Market Segmentation:

The report presents a detailed segmentation of the post-herpetic neuralgia treatment market based on treatment type, distribution channels, and region. The treatment types include drugs, patches, and steroid injectables. Within the drug segment, further subdivisions are made for anticonvulsants, antidepressants, and opioids.

Under the patches segment, there are subdivisions for lidocaine skin patches and capsaicin skin patches. Distribution channels comprise institutional sales, which encompass hospital pharmacies and clinics, and retail sales, which include retail pharmacies, drug stores, and mail-order pharmacies.

The post-herpetic neuralgia treatment market analysis covers regions including North America, Latin America, Europe, Asia Pacific excluding China, China, and the Middle East and Africa.

Table of Contents

1. Executive Summary

  • 1.1. Global Post Herpetic Neuralgia Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Drugs
        • 3.1.1.1.1. Anticonvulsants
        • 3.1.1.1.2. Antidepressants
        • 3.1.1.1.3. Opioids
      • 3.1.1.2. Patches
        • 3.1.1.2.1. Lidocaine Patches
        • 3.1.1.2.2. Capsaicin Patches
      • 3.1.1.3. Steroid Injectable
  • 3.2. Global Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Institutional Sales
        • 3.2.1.1.1. Hospital Pharmacies
        • 3.2.1.1.2. Clinics
      • 3.2.1.2. Retail Sales
        • 3.2.1.2.1. Retail Pharmacies
        • 3.2.1.2.2. Drug Stores
        • 3.2.1.2.3. Mail Order Pharmacies
  • 3.3. Global Post Herpetic Neuralgia Treatment Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. North America
      • 3.3.1.2. Europe
      • 3.3.1.3. Asia Pacific
      • 3.3.1.4. Latin America
      • 3.3.1.5. Middle East & Africa

4. North America Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Drugs
        • 4.1.1.1.1. Anticonvulsants
        • 4.1.1.1.2. Antidepressants
        • 4.1.1.1.3. Opioids
      • 4.1.1.2. Patches
        • 4.1.1.2.1. Lidocaine Patches
        • 4.1.1.2.2. Capsaicin Patches
      • 4.1.1.3. Steroid Injectable
  • 4.2. North America Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Institutional Sales
        • 4.2.1.1.1. Hospital Pharmacies
        • 4.2.1.1.2. Clinics
      • 4.2.1.2. Retail Sales
        • 4.2.1.2.1. Retail Pharmacies
        • 4.2.1.2.2. Drug Stores
        • 4.2.1.2.3. Mail Order Pharmacies
  • 4.3. North America Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. U.S. Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 4.3.1.2. U.S. Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.3.1.3. Canada Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 4.3.1.4. Canada Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Drugs
        • 5.1.1.1.1. Anticonvulsants
        • 5.1.1.1.2. Antidepressants
        • 5.1.1.1.3. Opioids
      • 5.1.1.2. Patches
        • 5.1.1.2.1. Lidocaine Patches
        • 5.1.1.2.2. Capsaicin Patches
      • 5.1.1.3. Steroid Injectable
  • 5.2. Europe Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Institutional Sales
        • 5.2.1.1.1. Hospital Pharmacies
        • 5.2.1.1.2. Clinics
      • 5.2.1.2. Retail Sales
        • 5.2.1.2.1. Retail Pharmacies
        • 5.2.1.2.2. Drug Stores
        • 5.2.1.2.3. Mail Order Pharmacies
  • 5.3. Europe Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Germany Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.2. Germany Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.3. U.K. Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.4. U.K. Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.5. France Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.6. France Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.7. Italy Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.8. Italy Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.9. Turkey Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.10. Turkey Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.11. Russia Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.12. Russia Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.3.1.13. Rest of Europe Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 5.3.1.14. Rest of Europe Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Drugs
        • 6.1.1.1.1. Anticonvulsants
        • 6.1.1.1.2. Antidepressants
        • 6.1.1.1.3. Opioids
      • 6.1.1.2. Patches
        • 6.1.1.2.1. Lidocaine Patches
        • 6.1.1.2.2. Capsaicin Patches
      • 6.1.1.3. Steroid Injectable
  • 6.2. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Institutional Sales
        • 6.2.1.1.1. Hospital Pharmacies
        • 6.2.1.1.2. Clinics
      • 6.2.1.2. Retail Sales
        • 6.2.1.2.1. Retail Pharmacies
        • 6.2.1.2.2. Drug Stores
        • 6.2.1.2.3. Mail Order Pharmacies
  • 6.3. Asia Pacific Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. China Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.2. China Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.3. Japan Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.4. Japan Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.5. South Korea Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.6. South Korea Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.7. India Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.8. India Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.9. Southeast Asia Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.10. Southeast Asia Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.3.1.11. Rest of Asia Pacific Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 6.3.1.12. Rest of Asia Pacific Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Drugs
        • 7.1.1.1.1. Anticonvulsants
        • 7.1.1.1.2. Antidepressants
        • 7.1.1.1.3. Opioids
      • 7.1.1.2. Patches
        • 7.1.1.2.1. Lidocaine Patches
        • 7.1.1.2.2. Capsaicin Patches
      • 7.1.1.3. Steroid Injectable
  • 7.2. Latin America Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Institutional Sales
        • 7.2.1.1.1. Hospital Pharmacies
        • 7.2.1.1.2. Clinics
      • 7.2.1.2. Retail Sales
        • 7.2.1.2.1. Retail Pharmacies
        • 7.2.1.2.2. Drug Stores
        • 7.2.1.2.3. Mail Order Pharmacies
  • 7.3. Latin America Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Brazil Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.2. Brazil Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.3. Mexico Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.4. Mexico Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.5. Argentina Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.6. Argentina Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.3.1.7. Rest of Latin America Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 7.3.1.8. Rest of Latin America Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, by Treatment Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Drugs
        • 8.1.1.1.1. Anticonvulsants
        • 8.1.1.1.2. Antidepressants
        • 8.1.1.1.3. Opioids
      • 8.1.1.2. Patches
        • 8.1.1.2.1. Lidocaine Patches
        • 8.1.1.2.2. Capsaicin Patches
      • 8.1.1.3. Steroid Injectable
  • 8.2. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Institutional Sales
        • 8.2.1.1.1. Hospital Pharmacies
        • 8.2.1.1.2. Clinics
      • 8.2.1.2. Retail Sales
        • 8.2.1.2.1. Retail Pharmacies
        • 8.2.1.2.2. Drug Stores
        • 8.2.1.2.3. Mail Order Pharmacies
  • 8.3. Middle East & Africa Post Herpetic Neuralgia Treatment Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. GCC Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.2. GCC Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.3. South Africa Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.4. South Africa Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.5. Egypt Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.6. Egypt Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.7. Nigeria Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.8. Nigeria Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.9. Nigeria Post Herpetic Neuralgia Treatment Market Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.3.1.10. Rest of Middle East & Africa Post Herpetic Neuralgia Treatment Market by Treatment Type, Value (US$ Bn), 2018 - 2031
      • 8.3.1.11. Rest of Middle East & Africa Post Herpetic Neuralgia Treatment Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. Treatment Type vs Distribution Channel Heatmap
  • 9.2. Manufacturer vs Distribution Channel Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Treatment Type Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Teva Pharmaceutical Industries Ltd.
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Treatment Type Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Mylan N.V.
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Treatment Type Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Endo Pharmaceuticals Inc.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Treatment Type Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Daiichi Sankyo
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Treatment Type Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Acorda Therapeutics
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Treatment Type Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Purdue Pharma L.P
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Treatment Type Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. Teikoku Pharma USA, Inc.
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Treatment Type Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Janssen Pharmaceuticals, Inc.
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Treatment Type Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations